CLPT ClearPoint Neuro Inc

Price (delayed)

$7.21

Market cap

$197.7M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.83

Enterprise value

$176.25M

ClearPoint Neuro's mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of ...

Highlights
The equity has soared by 63% from the previous quarter and by 6% YoY
ClearPoint Neuro's revenue has increased by 25% YoY and by 9% from the previous quarter
ClearPoint Neuro's net income has decreased by 14% YoY but it has increased by 7% from the previous quarter
ClearPoint Neuro's EPS has decreased by 12% YoY but it has increased by 8% from the previous quarter
The quick ratio has plunged by 56% YoY and by 30% from the previous quarter
CLPT's debt is up by 17% YoY

Key stats

What are the main financial stats of CLPT
Market
Shares outstanding
27.42M
Market cap
$197.7M
Enterprise value
$176.25M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.62
Price to sales (P/S)
7.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.74
Earnings
Revenue
$26.16M
EBIT
-$20.9M
EBITDA
-$19.24M
Free cash flow
-$12.79M
Per share
EPS
-$0.83
Free cash flow per share
-$0.5
Book value per share
$1.28
Revenue per share
$1.03
TBVPS
$2.06
Balance sheet
Total assets
$53.64M
Total liabilities
$19.05M
Debt
$13.9M
Equity
$34.58M
Working capital
$32.41M
Liquidity
Debt to equity
0.4
Current ratio
3.14
Quick ratio
2.5
Net debt/EBITDA
1.12
Margins
EBITDA margin
-73.5%
Gross margin
57.1%
Net margin
-78.8%
Operating margin
-80.1%
Efficiency
Return on assets
-43.9%
Return on equity
-76.9%
Return on invested capital
-88.1%
Return on capital employed
-54.3%
Return on sales
-79.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CLPT stock price

How has the ClearPoint Neuro stock price performed over time
Intraday
1.98%
1 week
-4.12%
1 month
27.61%
1 year
4.95%
YTD
6.19%
QTD
33.77%

Financial performance

How have ClearPoint Neuro's revenue and profit performed over time
Revenue
$26.16M
Gross profit
$14.94M
Operating income
-$20.97M
Net income
-$20.63M
Gross margin
57.1%
Net margin
-78.8%
ClearPoint Neuro's revenue has increased by 25% YoY and by 9% from the previous quarter
CLPT's net margin is up by 15% QoQ and by 9% YoY
The company's operating income fell by 15% YoY but it rose by 7% QoQ
ClearPoint Neuro's operating margin has increased by 15% from the previous quarter and by 8% YoY

Growth

What is ClearPoint Neuro's growth rate over time

Valuation

What is ClearPoint Neuro stock price valuation
P/E
N/A
P/B
5.62
P/S
7.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.74
ClearPoint Neuro's EPS has decreased by 12% YoY but it has increased by 8% from the previous quarter
The P/B is 88% below the 5-year quarterly average of 45.6 and 9% below the last 4 quarters average of 6.2
The equity has soared by 63% from the previous quarter and by 6% YoY
The price to sales (P/S) is 43% lower than the 5-year quarterly average of 12.4 but 3.1% higher than the last 4 quarters average of 6.8
ClearPoint Neuro's revenue has increased by 25% YoY and by 9% from the previous quarter

Efficiency

How efficient is ClearPoint Neuro business performance
ClearPoint Neuro's return on invested capital has shrunk by 83% YoY and by 10% QoQ
The return on equity has dropped by 62% year-on-year but it has grown by 8% since the previous quarter
CLPT's ROA is down by 36% YoY but it is up by 8% from the previous quarter
ClearPoint Neuro's ROS has increased by 15% from the previous quarter and by 8% YoY

Dividends

What is CLPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLPT.

Financial health

How did ClearPoint Neuro financials performed over time
The company's total assets is 182% higher than its total liabilities
The current ratio has plunged by 59% YoY and by 36% from the previous quarter
The quick ratio has plunged by 56% YoY and by 30% from the previous quarter
CLPT's debt is 60% lower than its equity
The equity has soared by 63% from the previous quarter and by 6% YoY
The debt to equity has declined by 39% since the previous quarter but it has increased by 11% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.